Houlihan Lokey Advises InTandem Capital Partners
Houlihan Lokey is pleased to announce that Vivo Infusion (Vivo), a portfolio company of InTandem Capital Partners (InTandem), has acquired Infusion Associates, a portfolio company of Boyne Capital (Boyne). The transaction closed on July 1, 2024.
Vivo is a leading provider of accessible, affordable, community-based infusion and injection care for patients suffering from compromised immune systems, cancer-related diagnoses, and other medical conditions. Vivo provides compassionate, expert care administered in safe, accessible facilities using efficient, cost-effective, and patient-focused best practices. Vivo currently serves communities in 15 states with plans to expand into additional markets.
InTandem is a private equity firm that invests in and helps accelerate the growth of select healthcare services companies. Its goal is to build excellent businesses of significant value, working collaboratively with its management team partners. InTandem is solely focused on investing in businesses that align closely with the Healthcare Quintuple Aim—the simultaneous pursuit of enhanced patient experience, elevated provider experience, improved clinical outcomes, greater healthcare equity, and lower cost of care delivery. The firm comprises former business executives and experienced investors and is uniquely qualified to provide strategic, acquisition, and operating expertise to help companies significantly increase their value and their contribution to an improved healthcare system. InTandem provides active support to the management of its portfolio companies directly and leverages its network of industry executives to augment its capabilities.
Infusion Associates is a leading provider of ambulatory infusion services across the Midwest U.S. The company specializes in the long-term treatment of chronic health conditions across a range of therapeutic areas, including neurology, gastroenterology, rheumatology, and immunology. With an extensive formulary of more than 160 therapies and a dedication to clinical research that has kept the company at the forefront of emerging treatment pathways, Infusion Associates has developed a reputation for high-quality patient care and management of complex conditions in an affordable and accessible setting.
Boyne is a Florida-based private equity firm focused on investments in lower-middle-market companies. Founded in 2006, Boyne has successfully invested in a broad range of industries, including healthcare services, consumer products, niche manufacturing, and business and financial services, among others. Beyond financial resources, Boyne provides industry and operational expertise to its portfolio companies and partners with management to drive both company performance and growth. Boyne specializes in providing the capital necessary to fund corporate growth and facilitate owners’ and shareholders’ partial or full exit.
This deal further highlights Houlihan Lokey’s leadership in the pharmacy and infusion-related services sector, becoming its eighth closed M&A transaction in this space since 2020. Houlihan Lokey’s Healthcare Group is among the largest dedicated healthcare investment banking groups in the world. In 2023, the group closed 34 transactions and was ranked by LSEG (formerly Refinitiv) as the No. 1 advisor for all global healthcare M&A transactions.*
Houlihan Lokey served as the financial advisor to InTandem Capital Partners.
*Excludes accounting firms and brokers.
RELATED: Healthcare